ABOUT US We want to challenge and improve today's standardized treatments with the help of our AI-Immunology™ platform. In the field of oncology, we create truly personalized therapies where one size fits one, and only one. Within infectious diseases, we use the technology to design next-generation vaccines to address unmet medical needs.
Our purpose
Modern medicine is advancing rapidly, yet too many people still die of cancer, drug-resistant bacteria, and other infectious diseases. The demand for new, efficient drugs has never been higher and will only grow. Every day, our artificial intelligence (AI) technology is bringing us closer to a future where we will be able to treat a wide range of critical diseases in a targeted, patient-specific way. We see an immense market for new, efficient, and personalized drugs, as well as a substantial way to improve patients' quality of life. This is why our purpose is: Decoding the human immune system to develop novel vaccines for cancer and infectious diseases with our AI-Immunology™ platform.
How we do it
At Evaxion, our AI-Immunology™ platform is at the heart of our work to revolutionize drug development and ultimately save the lives of patients. We bridge AI technology, bioinformatics, and drug development to bring novel immunotherapies to patients. We have used our AI to generate a broad pipeline of candidate immunotherapies that address two of the most significant unmet medical needs worldwide: cancer and infectious diseases.
Why AI?
The predictive power of our AI models comes from our ability to process and interpret vast amounts of data. These data are transformed into advanced algorithms that we believe can accurately predict cellular interactions and identify the right target to stimulate a relevant, potentially lifesaving response.
Contact
EVAXION is located in Hørsholm, Denmark. For further information, please contact us here.
Leadership Team Evaxion is comprised of an experienced leadership team and advisors with a proven track record from leading pharmaceutical companies and universities.
Christian Kanstrup
Christian Kanstrup has more than 25 years of experience in the life science industry, coming from a position of Executive Vice President at Mediq before joining Evaxion. Prior to that, Christian held various senior management roles at Novo Nordisk A/S.
Christian also holds various board and advisory positions in the life science industry, advising on corporate strategy and company growth.
Andreas Holm Mattsson
Andreas is an experienced bioinformatician from the Technical University of Denmark. Prior to Evaxion, Andreas spent six years at Novo Nordisk developing in silico platforms.
Since the founding of Evaxion in 2008, Andreas has worked on developing Evaxion's in silico platforms, including PIONEER and EDEN, and numerous other in silico tools enabling vaccine discovery in the area of infectious diseases and immuno-oncology.
Birgitte Rønø
Birgitte Rønø, PhD, joined Evaxion as Senior Director of Immuno-Oncology in 2017 and was appointed Chief Scientific Officer in September 2021.
Dr. Rønø has more than 15 years' experience in biopharmaceutical drug discovery from academia and industry and received her PhD in experimental oncology and immunology from National Institutes of Health, Bethesda, USA, and Copenhagen University Hospital, Denmark.
Thomas Schmidt
Thomas Schmidt joined Evaxion in 2024, bringing more than 29 years of financial management experience from across different industries, with more than 25 years of these being based in the life science industry, including roles as country Managing Director and Chief Financial Officer in Roche and Group CFO in Ambu.
Mr. Schmidt holds a Master of Science in Business Economics and Auditing from Copenhagen Business School and has undergone training and preparation for State Authorized Public Accountant (CPA) exam.
Board of Directors Evaxion is comprised of an experienced leadership team and advisors with a proven track record from leading pharmaceutical companies and universities.
Mrs. Søgaard served for 22 years at the Kammeradvokaten/Law Firm Poul Schmith as a corporate lawyer, partner and board member. After making partner in January of 2000, Mrs. Søgaard primarily worked with technology and processes to acquire technology solutions at the firm and ultimately served on the firm’s board of directors beginning in 2014. After leaving the firm in 2017, Mrs. Søgaard served on various boards including How to Robot, a platform company supporting the acquisition of physical robots for customers and suppliers and Altapay, a payment solution company. From 2018 to 2020, Mrs. Søgaard joined Evaxion Biotech and served as an executive, corporate lawyer and legal advisor to the company.
Lars Staal Wegner received his M.D. from the University of Southern Denmark. He is a Partner at Bristlecone Pacific, a venture capital firm that invests in evidence-based solutions to extend healthy human lifespan. Dr. Wegner brings in deep experience in artificial intelligence and biotechnology finance, business development, and research. He has helped build numerous biotech, diagnostics, and IT companies, sitting on multiple boards. Earlier in his career, he held different roles of increasing responsibility at Bavarian Nordic A/S, including as Vice President of Commercial Affairs, during which time he contributed to developing the company’s Ebola vaccine and different previous roles in Pfizer. Lars Staal Wegner has previously been Chairman (2013-2014), board member (2015-2016) and CEO of Evaxion (2017-2022).
Roberto was one of the first external investors in Evaxion. Roberto has over 20 years of pharmaceutical experience. He has been country GM and also occupied the position of Regional Leader of the Latin American Region for Teva from 2013 until 2015. He currently manages Viax Dental Technologies, an R&D venture in the dental field. He has a B.S. of Economics from Universidad Católica Andrés Bello in Caracas, Venezuela and an MBA from Fuqua School of Business at Duke University.
Lars served for 35 years as an employee and partner of PwC in Denmark, including four years as Chairman of the Board. His clients included a number of major Danish pharmaceutical and biotech companies, where he advised Boards and executives on management remuneration. He currently serves on the Boards of a number of companies, including Gaming Investment A/S and MTI Caretag Invest A/S, both of which as Chairman, and Ascendis Pharma A/S, a U.S. publicly traded company listed on the NASDAQ, as a Board member, Audit Committee Chair and member of the Remuneration Committee.
Careers
Play an instrumental role in the expansion of Evaxion and explore our open positions. At Evaxion, you will work in a fast-paced environment that cultivates a collaborative and innovative spirit. We support one another’s growth and success, and believe our core is built upon diverse abilities.
